KCIA
ABBV icon

Kingsbury Capital Investment Advisors’s AbbVie ABBV Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$800K Buy
3,178
+9
+0.3% +$1.94K 0.68% 42
2026
Q1 		$689K Buy
+3,169
New +$703K 0.65% 41
2022
Q3 		$343K Sell
2,553
-32
-1% -$4.59K 0.52% 42
2022
Q2 		$396K Sell
2,585
-623
-19% -$95.2K 0.55% 45
2022
Q1 		$520K Buy
+3,208
New +$466K 0.57% 37

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kingsbury Capital Investment Advisors's ABBV Position: Q2 2026 in Review

Kingsbury Capital Investment Advisors increased its AbbVie (ABBV) stake by 0.28% in Q2 2026, buying an estimated $1.94K and bringing the position to 3,178 shares worth $800K. The position accounts for 0.68% of the portfolio, ranked #42.

Kingsbury Capital Investment Advisors first reported a position in ABBV in Q1 2022 and has held it in 5 quarters since. 4,231 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Kingsbury Capital Investment Advisors held 3,178 shares of AbbVie worth $800K as of Q2 2026.
  • Kingsbury Capital Investment Advisors bought 9 AbbVie shares in Q2 2026, an estimated $1.94K.
  • AbbVie made up 0.68% of Kingsbury Capital Investment Advisors's portfolio in Q2 2026, its #42 holding.
  • Kingsbury Capital Investment Advisors first reported a position in AbbVie in Q1 2022 and has held it in 5 quarters since.
  • 4,231 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q2 2026, filed 25 Aug 2026.